Kazia updates ADR for 266,666 ADSs, taps JPMorgan

Kazia Therapeutics updates its F-1 prospectus to reflect a new ADR depositary with JPMorgan while keeping ADS trading and holder positions unchanged.

Available on EDGAR 09/18/2026 - 04:07 PM EDT Accepted by SEC EDGAR 09/18/2026 - 04:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kazia Therapeutics Limited (KZIA) filed a prospectus supplement updating a prior Form F-1 prospectus covering 266,666 American Depositary Shares (ADSs) representing 133,333,000 ordinary shares. The supplement incorporates a new Form 6-K describing changes to the company’s American Depositary Receipt (ADR) program.

Effective with this update, Kazia appointed JPMorgan Chase Bank, N.A. as sole depositary for its ADR program, replacing The Bank of New York Mellon, under a Second Amended and Restated Deposit Agreement. Each ADS represents 500 ordinary shares, and the ADSs continue trading on Nasdaq under the symbol KZIA. The company states that the transition should be seamless and that ADS holders do not need to take any action; existing positions remain in place. The last reported sale price on Nasdaq was $10.86 per ADS on September 17, 2026.

Key Figures

ADSs covered: 266,666 ADSs Ordinary shares represented: 133,333,000 ordinary shares ADS ratio: 1 ADS = 500 ordinary shares +2 more

5 metrics

ADSs covered 266,666 ADSs Number of American Depositary Shares referenced in the updated prospectus

Ordinary shares represented 133,333,000 ordinary shares Total ordinary shares represented by the 266,666 ADSs

ADS ratio 1 ADS = 500 ordinary shares Ratio under the Second Amended and Restated Deposit Agreement with JPMorgan

Last reported ADS price $10.86 per ADS Closing sale price on Nasdaq Capital Market on September 17, 2026

Form F-3 file numbers incorporated by reference 333-276091, 333-281937, 333-294392 Registration statements into which this Form 6-K information is incorporated

Key Terms

American Depositary Shares, American Depositary Receipt, Deposit Agreement, Form F-6, +1 more

5 terms

American Depositary Shares financial

"JPMorgan will issue American Depositary Shares (“ADSs”), each representing"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

American Depositary Receipt financial

"sole depositary for the Company’s American Depositary Receipt (“ADR”) program"

An American depositary receipt (ADR) is a certificate that represents shares of a foreign company traded on U.S. stock exchanges. It allows investors to buy and sell parts of a foreign company's stock easily, much like purchasing shares of a company based in their own country. ADRs make international investing more convenient and accessible for U.S. investors.

Deposit Agreement financial

"entered into a Second Amended and Restated Deposit Agreement (the “Deposit Agreement”)"

A deposit agreement is a written contract between a customer and a financial institution that outlines the terms for opening and maintaining a deposit account, such as a savings or checking account. It explains important details like how funds can be accessed, any fees involved, and the institution’s responsibilities. For investors, understanding this agreement is important because it clarifies their rights and the rules governing their deposited funds.

Form F-6 regulatory

"JPMorgan has filed a Registration Statement on Form F-6 with the"

Form F-6 is an SEC registration form used when a U.S. depositary bank creates American Depositary Receipts (ADRs), which are certificates that let U.S. investors buy and sell shares of a foreign company as if they were domestic stocks. Think of an ADR as a local-language label placed on a foreign product: it makes the foreign share easier to trade and settle in U.S. markets, increasing accessibility, liquidity and investor choice while bringing certain U.S. disclosure and regulatory oversight.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kazia Therapeutics (KZIA) disclose in this 424B3 prospectus supplement?

Kazia Therapeutics updates a prior Form F-1 prospectus for 266,666 ADSs, incorporating a Form 6-K that details the appointment of JPMorgan as the new ADR depositary while maintaining Nasdaq trading under KZIA and leaving ADS holder positions unchanged.

How many ADSs and ordinary shares are covered for KZIA in this supplement?

The supplement relates to 266,666 American Depositary Shares, each representing 500 ordinary shares, for a total of 133,333,000 ordinary shares, consistent with the underlying Form F-1 prospectus it updates.

What change does KZIA make to its ADR program in this filing?

Kazia appoints JPMorgan Chase Bank, N.A. as the sole depositary for its ADR program, replacing The Bank of New York Mellon, under a Second Amended and Restated Deposit Agreement, while keeping the existing ADS structure and Nasdaq listing.

What is the current ADS-to-ordinary-share ratio for KZIA?

Each American Depositary Share of Kazia represents 500 of the company’s ordinary shares, as stated in connection with the new Deposit Agreement with JPMorgan for the ADR program.

Do KZIA ADS holders need to take any action due to the new depositary?

No. The company states that ADS holders do not need to take any action at this time, and the transition to JPMorgan as depositary is expected to be seamless, with existing ADS positions continuing without interruption.

What was the recent Nasdaq trading price for KZIA ADSs mentioned here?

The last reported sale price of Kazia’s ADSs on The Nasdaq Capital Market was $10.86 per ADS on September 17, 2026, providing a recent market reference for the securities covered by the prospectus supplement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-284606

PROSPECTUS SUPPLEMENT

(to Prospectus dated December 22, 2025)

266,666 American Depositary Shares representing

133,333,000

Ordinary Shares

 

Kazia Therapeutics Limited

This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December 22, 2025 (the “Prospectus”), which forms a part of our Registration Statement on Form F-1 (Registration No. 333-284606), as amended, with the information contained in our current report on Form 6-K, furnished to the Securities and Exchange Commission on September 18, 2026 (the “September 18, 2026 Form 6-K”). Accordingly, we have attached the September 18, 2026 Form 6-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

The ADSs are listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “KZIA.” On September 17, 2026, the last reported sale price of the ADSs on Nasdaq was $10.86 per ADS.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 of the Prospectus and the “Risk Factors” in “Item 3. Key Information-D. Risk Factors” of our most recent Annual Report on Form 20-F, which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is September 18, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 000-29962

Kazia Therapeutics Limited.

(Exact Name of Registrant as Specified in Its Charter)

Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On September 18, 2026, Kazia Therapeutics Limited (the “Company”) appointed JPMorgan Chase Bank, N.A. (“JPMorgan”) as the sole depositary for the Company’s American Depositary Receipt (“ADR”) program, replacing The Bank of New York Mellon (“BNY Mellon”). In connection with the appointment, the Company and JPMorgan entered into a Second Amended and Restated Deposit Agreement (the “Deposit Agreement”), pursuant to which JPMorgan will issue American Depositary Shares (“ADSs”), each representing five hundred (500) of the Company’s ordinary shares. The ADSs will continue to trade on The Nasdaq Capital Market under the symbol “KZIA.” JPMorgan has filed a Registration Statement on Form F-6 with the Securities and Exchange Commission in connection with the new ADR program. ADS holders do not need to take any action at this time. The transition is expected to be seamless, and existing ADS holders will continue to hold their positions without interruption.

Incorporation by Reference

The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form F-3 (File Nos. 333-276091, 333-281937 and 333-294392).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Kazia Therapeutics Limited.
Date: September 18, 2026	By:	/s/ John Friend
	Name:	John Friend
	Title:	Chief Executive Officer

2